Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis

Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis

Abstract Background Our aim was to compare the efficacy of rituximab, tocilizumab, and abatacept in individuals with rheumatoid arthritis (RA) refractory to treatments with MTX or TNFi agents. Methods We searched 6 databases until January 2023 for phase 2–4 RCTs evaluating patients with RA refractor...

Full description

Bibliographic Details
Main Authors: Alisson Pugliesi, Amanda Borges de Oliveira, Ana Beatrice Oliveira, Ricardo Xavier, Licia Maria Henrique da Mota, Manoel Barros Bertolo, Miguel Angel Gonzalez-Gay, Gustavo Citera, Luiz Sergio Fernandes de Carvalho
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Advances in Rheumatology
Subjects:
Rheumatoid arthritis
Rituximab
Abatacept
Tocilizumab
bDMARD
American college of rheumatology
Online Access:https://doi.org/10.1186/s42358-023-00298-z

Internet

https://doi.org/10.1186/s42358-023-00298-z

Similar Items